A donation of $50 will be used for reagents for undertaking blood and tumor sample tests for 1 week. Donors who permit recognition will be named as "Reagent Supporters" on the AUSiMED website.
Donations are used to develop a critically needed new breast cancer treatment for women with breast cancer resistant to all forms of treatment. As a result they have no prospect of survival. In Australia, this relates to 20% of breast cancer patients (almost 3000 deaths in 2011).
Surviving breast cancer is particularly difficult for women with inherited BRCA1 or 2 mutated genes. Their tumours tend to become resistant to all forms of treatment.
Angelina Jolie inherited a BRCA1 mutated gene. Her risk of getting breast cancer from this mutated gene was over 90% and her risk of getting ovarian cancer was over 50%. Because women with this mutated gene tend to be resistant to all forms of treatment, Angelina Jolie had both her breasts and her ovaries removed to prevent getting breast and ovarian cancer.
Inherited BRCA1 and 2 mutated genes is a major issue for the Jewish community as 1 in 40 (2.5%) Ashkenazi Jewish women worldwide carry the mutated genes which is TEN times more prevalent amongst them than the rest of the population.
AUSiMED has identified an outstanding research team in Australia at the Walter and Eliza Hall Institute in Melbourne and in Israel at the Sheba Medical Centre in Tel Aviv.They both have exceptional track records of success. Together they have developed an exciting collaborative research project to find out how breast cancers become resistant to treatments and to work out how to stop this resistance process. The project is so impressive that the Australian team have been recently awarded with two years of funding for the proposed project by the National Breast Cancer Foundation. As a result, AUSiMED are now seeking to raise funds for the Israeli team, so they can also get started on the project.